Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab
Phase 1Active 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Relapsed/Refractory Multiple Myeloma
Conditions
Relapsed/Refractory Multiple Myeloma
Trial Timeline
Oct 20, 2022 โ Sep 1, 2033
NCT ID
NCT05259839About Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + Daratumumab is a phase 1 stage product being developed by AbbVie for Relapsed/Refractory Multiple Myeloma. The current trial status is active. This product is registered under clinical trial identifier NCT05259839. Target conditions include Relapsed/Refractory Multiple Myeloma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05259839 | Phase 1 | Active |
Competing Products
20 competing products in Relapsed/Refractory Multiple Myeloma